We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| argenx SE | NASDAQ:ARGX | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.08 | -1.05% | 382.92 | 379.66 | 380.35 | 2,287 | 12:05:15 |
From Jun 2023 to Jun 2024
By Dean Seal
Shares of Argenx dropped after the company said a study of its treatment for primary immune thrombocytopenia didn't meet its primary or secondary endpoints.
The stock fell 10% to $445 in premarket trading. Shares had gained 31% year-to-date when the market closed Monday.
The immunology company said early Tuesday morning that its study evaluating Vyvgart Hytrulo didn't meet the primary endpoint of a sustained platelet count response in patients with chronic primary immune thrombocytopenia, an autoimmune disorder.
"This is not the outcome we had hoped for patients," Chief Medical Officer Luc Truyen said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 06:48 ET (11:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year argenx Chart |
1 Month argenx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
